Amygdala Pharmaceutical presents BEVRIXA-50 Tablets, formulated with Brivaracetam 50 mg for advanced management of partial-onset seizures. BEVRIXA-50 provides faster onset of action, higher SV2A binding affinity, and enhanced blood-brain barrier permeability. It effectively reduces excitatory neurotransmitter release and supports robust seizure control in epilepsy, including patients intolerant or allergic to other antiepileptic drugs.
